Fig. 3
From: The great debate at “Melanoma Bridge 2018”, Naples, December 1st, 2018
Is anti CTLA-4 still the optimal drug to combine with anti PD-L1? Yes or no. Audience response before and after debate
Fig. 3 | Journal of Translational Medicine
